SPX4,240.33-43.41 -1.01%
DIA338.18-1.74 -0.51%
IXIC12,734.07-231.28 -1.78%

Akari Therapeutics Announces Results From Recent Pre-Clinical Studies Of Investigational PASylated Nomacopan That Support The Potential To Advance Research Toward IND/IMPD For Clinical Trials In Geographic Atrophy

Positive results from recent pre-clinical studies support the potential of long-acting PASylated nomacopan to advance toward IND/IMPD for clinical trials in geographic atrophy (GA) in dry age-related macular

Benzinga · 07/28/2022 08:15
  • Positive results from recent pre-clinical studies support the potential of long-acting PASylated nomacopan to advance toward IND/IMPD for clinical trials in geographic atrophy (GA) in dry age-related macular degeneration (dAMD), a disease with no approved treatments
  • New PK measurements indicate the half-life within the eye of intravitreally injected early generation PAS-nomacopan (also referred to as PAS600 nomacopan) in a standard ophthalmic pre-clinical model can be accurately predicted; results support Akari’s continuing work to develop new generation PAS-nomacopan that may enable dosing intervals for patients of more than three months between intravitreal injections
  • Tolerability of early generation PAS-nomacopan was demonstrated across multiple measures in a standard ophthalmic pre-clinical model
  • These new data showing extended dose intervals, together with data previously presented, showing LTB4 inhibition by PAS-nomacopan may also reduce the risk of sight-threatening choroidal neovascularization (CNV), suggest PAS-nomacopan may be a potential novel and effective treatment option for GA